image: He will be sharing his insights on the panel “Pharma Drug Discovery & Development AI Strategy” on 3:30 p.m, Sep. 30. All those interested are encouraged to register at https://aaihmembermeeting.org/.
Credit: Insilico Medicine
As one of the founding members of the Alliance for Artificial Intelligence in Healthcare (AAIH), Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, is proud to announce that Alex Zhavoronkov, PhD, founder and co-CEO of Insilico Medicine will be attending the AAIH Annual Members’ Meeting on the Genentech Campus in South San Francisco, California, where he will be sharing his insights on the panel “Pharma Drug Discovery & Development AI Strategy” on 3:30 p.m, Sep. 30. All those interested are encouraged to register at https://aaihmembermeeting.org/.
Launched in 2019, the AAIH brings together industry, academia, research institutions, government NGOs, key opinions leaders, and other international stakeholders, striving for the advancement and use of artificial intelligence in healthcare to improve patients’ lives, and healthcare systems that are more efficient, sustainable, and accessible.
In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico keeps integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning across biology, chemistry and clinical development. Powered by Pharma.AI, Insilico has nominated 19 preclinical candidates in its comprehensive portfolio of over 30 assets since 2021 and has received IND approval for 9 molecules.
In early 2024, Insilico published a Nature Biotechnology paper presenting the entire R&D journey from AI algorithms to Phase II clinical trials of ISM001_055, the company’s lead drug pipeline with AI-discovered target and AI-designed structure. Following that, Insilico has recently announced positive preliminary results from a Phase IIa trial (NCT05938920), where ISM001_055 showed dose-dependent response in forced vital capacity (FVC), after only 12 weeks of dosage.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com